Pierre‐Éric Juif

Novartis (Switzerland) — Switzerland

Biochemistry, Genetics and Molecular Biology · Life Sciences

16h-index662citations45works0.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Sphingolipid Metabolism and Signaling(13), Stress Responses and Cortisol(9), Pain Mechanisms and Treatments(8), Systemic Lupus Erythematosus Research(4), Lipid Membrane Structure and Behavior(4)

Publications45 total

Correction: Preclinical discovery and initial clinical data of WVT078, a BCMA × CD3 bispecific antibody
Leukemia·2025Open Access
Multiple‐dose pharmacokinetics of cenerimod and the effect of charcoal on its elimination
The Journal of Clinical Pharmacology·2024Open Access
Phase I/Ib, open-label, multicenter, dose-escalation study of the anti-TGF-β monoclonal antibody, NIS793, in combination with spartalizumab in adult patients with advanced tumors
Journal for ImmunoTherapy of Cancer·2023· 33 citedOpen Access
Preclinical discovery and initial clinical data of WVT078, a BCMA × CD3 bispecific antibody
Leukemia·2023· 13 cited
Lack of Effect of Cenerimod, a Selective S1P1 Receptor Modulator, on the Pharmacokinetics of a Combined Oral Contraceptive
International Journal of Molecular Sciences·2022· 1 citedOpen Access
P937: PRECLINICAL DISCOVERY AND EARLY FINDINGS FROM THE PHASE 1, DOSE-ESCALATION STUDY OF WVT078, A BCMA-CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH R/R MULTIPLE MYELOMA
HemaSphere·2022· 7 citedOpen Access
Clinical Pharmacology of Clazosentan, a Selective Endothelin A Receptor Antagonist for the Prevention and Treatment of aSAH-Related Cerebral Vasospasm
Frontiers in Pharmacology·2021· 28 citedOpen Access
Insights from In Vitro and Clinical Data to Guide Transition from the Novel P2Y12 Antagonist Selatogrel to Clopidogrel, Prasugrel, and Ticagrelor
Thrombosis and Haemostasis·2021· 11 cited
PK/PD modeling of a clazosentan thorough QT study with hysteresis in concentration-QT and RR-QT
Journal of Pharmacokinetics and Pharmacodynamics·2021· 7 cited
Pharmacokinetics and Pharmacodynamics of Cenerimod, A Selective S1P<sub>1</sub>R Modulator, Are Not Affected by Ethnicity in Healthy Asian and White Subjects
Clinical and Translational Science·2020· 4 citedOpen Access
Association Between Vomiting and QT Hysteresis: Data from a TQT Study with the Endothelin A Receptor Antagonist Clazosentan
The AAPS Journal·2020· 5 cited
Modelling pharmacokinetics and pharmacodynamics of the selective S1P<sub>1</sub> receptor modulator cenerimod in healthy subjects and systemic lupus erythematosus patients
British Journal of Clinical Pharmacology·2019· 6 citedOpen Access
Cardiodynamic Interactions between Two S1P1 Receptor Modulators in an Experimental Clinical Setting: Different Pharmacokinetic Properties as an Opportunity to Mitigate First-Dose Heart Rate Effects
International Journal of Molecular Sciences·2019· 11 citedOpen Access
Influence of Rifampin‐Mediated Organic Anion‐Transporting Polypeptide 1B1/1B3 Inhibition on the Pharmacokinetics of Clazosentan
Clinical and Translational Science·2019· 7 citedOpen Access
Issue Information
The Journal of Clinical Pharmacology·2018Open Access
Pharmacological rescue of nociceptive hypersensitivity and oxytocin analgesia impairment in a rat model of neonatal maternal separation
Pain·2018· 25 cited
Clinical Pharmacology of the Reversible and Potent P2Y<sub>12</sub> Receptor Antagonist ACT‐246475 After Single Subcutaneous Administration in Healthy Male Subjects
The Journal of Clinical Pharmacology·2018· 35 cited
Accelerated Development of the Dual Orexin Receptor Antagonist ACT‐541468: Integration of a Microtracer in a First‐in‐Human Study
Clinical Pharmacology & Therapeutics·2018· 65 citedOpen Access
Pharmacokinetics, Pharmacodynamics, Tolerability, and Food Effect of Cenerimod, a Selective S1P1 Receptor Modulator in Healthy Subjects
International Journal of Molecular Sciences·2017· 16 citedOpen Access
Metabolite profiling in early clinical drug development: current status and future prospects
Expert Opinion on Drug Metabolism & Toxicology·2017· 32 citedOpen Access
page 1 of 3Next →

Frequent Co-authors

Jasper Dingemanse(24), Pierrick Poisbeau(9), Mike Ufer(9), Ulrike Hanesch(9), Fernand Anton(9), Matthias Hoch(7), Andreas Krause(5), Margaux Boehler(4), Meggane Melchior(4), Adrien Lacaud(4), Vincent Lelièvre(4), Pascal Darbon(4), Andrea Vaclavkova(4), Yannick Goumon(3), Michael Dobrow(3), Vivien Zell(3), Daniele D’Ambrosio(3), Yaël C. Cohen(3), Fredrik Schjesvold(3), Kimberly Aardalen(3)